News

FY 2009 gross profit increased 96% to $39m, compared to $19.9m for FY2008 and gross margin increased 1,470 basis points to 73.2%. Operating expenses were $23.9m, up 97.7%

The relationship is expected to focus on the evaluation of MDRNA’s proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi). This marks MDRNA’s fourth

IFN-Beta, which is indicated for the treatment of multiple sclerosis (MS), is currently marketed by Merck Serono as Rebif and by Biogen Idec as Avonex. Prolor Biotech has

AmVac said that the novel technology, used for producing vaccines and has been developed at the research site in Martinsried near Munich, Germany, is completely covered by the

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, in the US, Canada and Mexico. A randomised, double-blind Phase 3 trial investigating Perifosine in combination with capecitabine (Xeloda)

Zipsor, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults, received FDA approval in June 2009. As per the agreement,

Almac Clinical Services said that this is the latest addition to the clinical services portfolio in improving the overall clinical label approval process. Traditionally manual in scope and

Simcere Pharmaceutical said that as a result of the investigation conducted by the local food and drug regulatory authority and local police department the SFDA found that the

Specifically, NICE’s FAD recommends Alimta as an option for the maintenance treatment of people with locally advanced or metastatic non-small cell lung cancer with other than predominantly squamous